POLMACOXIB 2mg. IP

A novel selective COX-2 inhibitor indicated for the management of pain and inflammation associated with osteoarthritis of the knee and hip. Polmacoxib works by inhibiting cyclooxygenase-2 (COX-2), thereby reducing the production of inflammatory mediators responsible for pain, swelling, and stiffness. It also exhibits carbonic anhydrase inhibitory activity, which may contribute to its favorable safety profile. Polmacoxib has demonstrated effective relief of osteoarthritis symptoms, including pain, stiffness, and impaired joint function. Clinical studies have shown significant improvements in symptom control with a rapid onset of action and good tolerability. Its dual mechanism of action and selective COX-2 inhibition make it a valuable option for patients requiring long-term management of osteoarthritis-related pain and inflammation.